BAFF-R CAR T Shows Durable Responses After CD19 Therapy
A peer-reviewed Lancet research letter reported the completed dose-escalation cohort of PMB-CT01, an autologous BAFF-R-directed CAR-T therapy, in nine adults with relapsed or refractory B-cell non-Hodgkin lymphoma. Seven of nine patients achieved complete response,…
